Pfizer to scale down early-stage rare disease research

January 6, 2023

US pharma giant Pfizer Inc. said on Thursday it is planning to realign its early-stage research into treatments for rare diseases and oncology, to focus on areas like rare and benign hematology.

Pfizer will also move away from having a rare disease research unit to align important rare disease programs to areas across its research units.

“We are refocusing our approach to early discovery and development research in rare disease and oncology,” a spokesperson said in a statement to Reuters, adding that the company will explore externalization opportunities for “a number of highly innovative, niche programs.”

Pfizer said its oncology research portfolio will become even more focused around breast, prostate and hematological cancer franchises.

Financial newspaper Barron’s first reported the news on Thursday. – Reuters

Disclaimer: Globalincomeexperts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company. Copyright © 2023 StartYourInvesting.com